Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1001
Experimental workflow for isolation and characterization of vascular tissue-derived exosomes.
Published 2025Subjects: -
1002
-
1003
-
1004
-
1005
miR-150-5p inhibition modulates pyroptosis and FoxO3a/ARC signaling in ApoE<sup>-/-</sup> mice.
Published 2025Subjects: -
1006
Therapeutic effects of miR-150-5p inhibition on ox-LDL-induced pyroptosis in RAW264.7 macrophages.
Published 2025Subjects: -
1007
-
1008
-
1009
-
1010
-
1011
-
1012
-
1013
-
1014
-
1015
-
1016
Increased oxidative stress, viral load and decreased survivability of N2a following RIG-I ablation.
Published 2011“…The mean fluorescence intensities obtained from each group are depicted in the figure. (1-Unstained, 2-Mock-infected; 3-JEV-infected, 4-JEV+Sc-MO, 5-JEV+rMO) (A). Immunoblot analysis to detect JEV NS-5 expression also showed enhancement in JEV+rMO when compared to either JEV-infected or JEV+ScMO groups (B&C). …”
-
1017
-
1018
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
Published 2019“…Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab), and the primary end point was the change in percentage of glycated haemoglobin (HbA1c%) (EudraCT: 2012-005370-62 ClinicalTrial.gov: NCT02236481).…”
-
1019
-
1020
mFIZZ1′ and mFIZZ1 decreased the IL-13 and IL-5 secretion of splenocytes.
Published 2013“…Recombinant mFIZZ1′ and mFIZZ1 expressed with or without hQSOX1b were used at 200 ng/ml. rRa is the bacterial recombinant FIZZ1 (200 ng/ml) from (Peprotech) and PBS is the control. (<b>A</b>) Recombinant mFIZZ1′ and mFIZZ1 co-expressed with hQSOX1b significantly decreased the IL-5 secretion compared to the proteins expressed alone. …”